EGFR Exon 19 Deletion clinical trials at UC Irvine
1 research study open to eligible people
open to eligible people ages 18 years and up
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-945, a selective EGFR inhibitor.
Orange, California and other locations